Hangzhou Zhuyangxin Pharmaceutical Co. Ltd.

Primary objective: To evaluate the bioequivalence of the test preparation (granisetron transdermal patch produced by Hangzhou Zhuyangxin Pharmaceutical Co., Ltd., specification 34.3mg/52cm2) and the reference preparation (granisetron transdermal patch certified by Kyowa Kirin Inc., specification 34.3mg/52cm2, trade name: Sancuso®) under topical conditions in Chinese healthy subjects using the main pharmacokinetic parameters (AUC and Cmax) of granisetron as bioequivalence evaluation indicators. Secondary objective: To observe the adhesion, irritation and safety of the test preparation and the reference preparation under topical conditions.

The main pharmacokinetic parameters (AUC and Cmax) of baricitinib were used as bioequivalence evaluation indicators to evaluate the bioequivalence of the test formulation (baricitinib tablets produced by Hangzhou Zhuyangxin Pharmaceutical Co., Ltd., strength: 4 mg) and the reference formulation (baricitinib tablets certified by Eli Lilly Nederland B.V., strength: 4 mg; trade name: Olumiant®) in Chinese healthy subjects in the fasting and fed state. The safety of the test formulation and the reference formulation in the fasting and fed state was observed.

A single-center, randomized, open, two-period crossover, two-formulation, two-sequence, single-dose administration design was used to compare the differences in absorption extent and rate between crisaborole ointment (specification: 2%) provided by Hangzhou Zhu Yangxin Pharmaceutical Co., Ltd. and crisaborole ointment (trade name: Staquis®/Staquis®, specification: 2%) licensed by Anacor Pharmaceuticals, Inc. in healthy Chinese people under fasting conditions, and to evaluate the safety of crisaborole ointment (specification: 2%) provided by Hangzhou Zhu Yangxin Pharmaceutical Co., Ltd.